药捷安康（南京）股份有限公司宣布，计划开展一项针对晚期非小细胞肺癌（NSCLC）的II期临床试验，该试验将评估其候选药物TT-973-MS与伏美替尼（Firmonertinib）联合疗法的安全性与有效性。这一举措标志着公司在该治疗领域研发进程的重要推进，旨在探索新的联合治疗方案，为患者提供更多潜在的治疗选择。
药捷安康（南京）股份有限公司宣布，计划开展一项针对晚期非小细胞肺癌（NSCLC）的II期临床试验，该试验将评估其候选药物TT-973-MS与伏美替尼（Firmonertinib）联合疗法的安全性与有效性。这一举措标志着公司在该治疗领域研发进程的重要推进，旨在探索新的联合治疗方案，为患者提供更多潜在的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.